和黄医药介绍联合治疗癌症的临床试验数据

2021-12-13 17:56

君实生物(01877.HK) 0
和黄医药(00013.HK) 0

04:50 AM EST, 12/13/2021 (MT Newswires) -- Hutchmed (HKG:0013) on Thursday presented results of certain clinical trials for its novel tumor inhibitor Surufatinib during the immuno-oncology congress of the European Society for Medical Oncology, according to a late Friday filing.

The dug was evaluated in the studies in combination with Shanghai Junshi Biosciences' (HKG:1877, SHA:688180) carcinoma treatment Toripalimab in treating certain advanced small cell lung, gastric, esophageal, and neuroendocrine cancers, the drugmaker said.

和黄医药介绍联合治疗癌症的临床试验数据

推荐文章

港股周报丨阿里重磅利好！周内暴涨14%；北水单周净买入港股608亿港元环比骤增8成

一周财经日历 | 万众瞩目！9月美联储利率决议来袭；三只港股新股即将上市

美股机会日报 | 金价年内或触及3800美元？国际大行集体唱多黄金！超微电脑涨超5%

能否赶上美联储下周议息会议？美参院就米兰理事提名表决时间定了

港股异动 | 重磅利好！阿里涨近7%，百度涨超6%

华盛早报 | 创近4年新高！阿里大涨8%；外资热情势不可挡！大摩：超九成美国投资者愿加仓中国资产

美股机会日报 | 美国8月CPI符合预期，初请失业金人数创近四年新高！“网红股”Opendoor股价大涨超30%

万亿南向“活水”疯狂抢筹！重仓阿里巴巴逾1200亿港元，如何抄“聪明钱”的作业？